Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001995 · ClinicalTrials.gov registry record · NA
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
A NA study, sponsored by Pharmacia.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT00001995 is a NA study that has completed, run by Pharmacia. The registered enrollment target is 200 participants.
The verdict
NCT00001995, a NA study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in patients with AIDS. To assess the safety of the drug regimen.
Interventions
- DRUG Rifabutin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001995
The ClinicalTrials.gov registry entry for NCT00001995 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifabutin is the first listed.
NCT00001995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001995 about?
NCT00001995 is a clinical study titled "A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS". To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in patients with AIDS. To assess the safety of the drug regimen.
What is the current status of trial NCT00001995?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants.
What interventions are being tested in trial NCT00001995?
The interventions under investigation include: Rifabutin (DRUG).
Who is sponsoring clinical trial NCT00001995?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.